Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tie2-Fc is a recombinant chimeric decoy receptor designed to inhibit the angiopoietin/Tie2 signaling pathway. It consists of the extracellular domain of the Tie2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2) receptor fused to the Fc region of a human immunoglobulin (IgG). Tie2-Fc acts as a molecular trap by binding to and sequestering circulating angiopoietins, including Ang-1, Ang-2, and Ang-4, thereby preventing them from interacting with the endogenous Tie2 receptors located on the surface of endothelial cells. This blockade suppresses pathological angiogenesis, vascular remodeling, and associated inflammatory processes. In preclinical research, Tie2-Fc has been utilized to study and treat conditions characterized by abnormal vessel growth and inflammation, such as rheumatoid arthritis and various solid tumors, where it helps reduce synovial inflammation, macrophage infiltration, and bone destruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tie2-Fc.